Neither side is blinking in an ongoing dispute tied to the looming introduction of a biosimilar version of one of the Philadelphia region's top selling medicines.
Pfizer said it is preparing to launch Inflectra,a biosimilar version of Horsham-based Janssen Biotech's Remicade product, late in November. Pfizer (NYSE: PFE), and which is based in unique York and has research operations in Collegeville,Pennsylvania, is marketing Inflectra In a partnership with Celltrion Healthcare Co. Ltd, or the South Korean…
Source: bizjournals.com